AstraZeneca CEO said Tuesday that the results of a study showing the COVID-19 vaccine had little effect on mild illnesses were of concern, but stressed that it should work against severe forms.
“It is of course a problem,” said Pascal Soriot of the study at a meeting of the World Health Organization.
“Even so, the patients in the study were mildly ill and we believe the vaccine should still protect against serious illness.”
AstraZeneca is a key supplier of a WHO-supported vaccine sharing program called COVAX.
(Except for the headline, this story was not edited by GossipMantri staff and published from a syndicated feed.)